- Previous Close
1.2200 - Open
1.2000 - Bid 0.9360 x 200
- Ask 1.5800 x 200
- Day's Range
1.1859 - 1.3100 - 52 Week Range
0.8700 - 10.2100 - Volume
261,306 - Avg. Volume
638,736 - Market Cap (intraday)
40.022M - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4800 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
www.outlooktherapeutics.comRecent News: OTLK
View MorePerformance Overview: OTLK
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OTLK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OTLK
View MoreValuation Measures
Market Cap
39.06M
Enterprise Value
64.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-268.11%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.81M
Diluted EPS (ttm)
-2.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
5.7M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-37.86M